Consensus cost-effectiveness model for treatment of chronic hepatitis B in Asia Pacific countries (Q38552485)

4 September 2017

title

Consensus cost-effectiveness model for treatment of chronic hepatitis B in Asia Pacific countries (English)

1 reference

4 September 2017

1 reference

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26202640%20AND%20SRC:MED&resulttype=core&format=json

14 June 2020

7

Teerha Piratvisuth

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26202640%20AND%20SRC:MED&resulttype=core&format=json

14 June 2020

1

Yock Young Dan

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26202640%20AND%20SRC:MED&resulttype=core&format=json

14 June 2020

author name string

John B Wong

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26202640%20AND%20SRC:MED&resulttype=core&format=json

14 June 2020

Saeed S Hamid

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26202640%20AND%20SRC:MED&resulttype=core&format=json

14 June 2020

Kwang-Hyub Han

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26202640%20AND%20SRC:MED&resulttype=core&format=json

14 June 2020

Ji Dong Jia

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26202640%20AND%20SRC:MED&resulttype=core&format=json

14 June 2020

Anna S F Lok

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26202640%20AND%20SRC:MED&resulttype=core&format=json

14 June 2020

Seng Gee Lim

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26202640%20AND%20SRC:MED&resulttype=core&format=json

14 June 2020

publication date

27 June 2014

1 reference

4 September 2017

published in

Hepatology international

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26202640%20AND%20SRC:MED&resulttype=core&format=json

14 June 2020

volume

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26202640%20AND%20SRC:MED&resulttype=core&format=json

14 June 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26202640%20AND%20SRC:MED&resulttype=core&format=json

14 June 2020

page(s)

382-394

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26202640%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s12072-014-9549-1

14 June 2020

exact match

0 references

cites work

Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures

1 reference

https://api.crossref.org/works/10.1007%2FS12072-014-9549-1

EASL Clinical Practice Guidelines: management of chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-014-9549-1

Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-014-9549-1

Treatment of chronic hepatitis B in Asia-Pacific countries: is the Asia-Pacific consensus statement being followed?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-014-9549-1

Treatment alternatives for chronic hepatitis B virus infection: a cost-effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-014-9549-1

Cost-utility analysis of tenofovir disoproxil fumarate in the treatment of chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-014-9549-1

Cost effectiveness of entecavir versus lamivudine with adefovir salvage in HBeAg-positive chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-014-9549-1

Markov models in medical decision making: a practical guide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-014-9549-1

Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-014-9549-1

Predicting cirrhosis risk based on the level of circulating hepatitis B viral load

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-014-9549-1

Lamivudine maintenance beyond one year after HBeAg seroconversion is a major factor for sustained virologic response in HBeAg-positive chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-014-9549-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-014-9549-1

Antiviral therapy for adults with chronic hepatitis B: a systematic review for a National Institutes of Health Consensus Development Conference

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-014-9549-1

Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-014-9549-1

Chronic hepatitis B: update 2009

21 January 2018

1 reference

12 December 2020

Changing seroprevalence of hepatitis B virus markers of adults in Singapore.

1 reference

12 December 2020

Consolidation therapy for HBeAg-positive Asian chronic hepatitis B patients receiving lamivudine treatment: a multicentre study

1 reference

12 December 2020

Changes in serum levels of HBV DNA and alanine aminotransferase determine risk for hepatocellular carcinoma

1 reference

12 December 2020

NIH consensus development statement on management of hepatitis B.

1 reference

12 December 2020